The Co-Pay for Brand-Name GEODON May Be Comparable to Its Generic With the GEODON Co-Pay Card1†‡
Each time you use the GEODON Co-Pay Card you may receive, if eligible:
- A monthly co-pay as little as $4
- Savings of up to $250 per month, or $3,000 per year
- Continued savings through December 31, 2017
†All commercial patients pay an average out-of-pocket cost of $11.96 per fill for generic ziprasidone HCl.
‡The amount you will pay may vary based on your insurance coverage.
Reference: 1. IMS PayerTrak data, July 2015.
Tools for patients taking GEODON
These tools encourage active participation in your treatment plan, including keeping track of your symptoms, encouraging an open dialogue with your doctor, and getting information on a savings offer from GEODON® (ziprasidone HCl).
GEODON Important Safety Information
Elderly patients with dementia-related psychosis (having lost touch with reality due to confusion and memory loss) treated with this type of medicine are at an increased risk of death, compared to placebo (sugar pill). GEODON® (ziprasidone HCl) is not approved for treating these patients.
GEODON ® (ziprasidone HCl) may increase the risk of changes to your heart rhythm. You should not take GEODON if you have certain kinds of heart conditions that change your heart rhythm, a recent heart attack, heart failure, or take certain medicines known to change heart rhythm. It is important to talk to your doctor about this possible side effect. Call your doctor right away if you faint, pass out, or feel a change in your heartbeat.
If you experience a high fever, stiff muscles, shaking, confusion, sweating, or increased heart rate or blood pressure, tell your doctor right away. These can be signs of a rare but potentially fatal condition called neuroleptic malignant syndrome (NMS).
Delayed-onset drug reaction called Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) can occur with ziprasidone. Signs of DRESS may include rash, fever, and swollen lymph nodes. Other severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome can occur with ziprasidone. Signs of Stevens-Johnson syndrome may include rash with blisters which could include ulcers in mouth, skin shedding, fever, and target-like spots in the skin. SCAR and DRESS are sometimes fatal; therefore call your health care professional(s) and seek immediate care if you develop any of these signs or symptoms.
If you experience abnormal or uncontrollable facial or body movements, notify your doctor. These could be a sign of tardive dyskinesia (TD), a potentially permanent condition whose risk increases with the length of treatment, but which can also occur after brief periods at low doses.
If you have diabetes or have risk factors or symptoms of diabetes, your blood sugar should be monitored. Symptoms include excessive thirst, urination, appetite, and weakness. High blood sugar has been reported with GEODON and medicines like it. In some cases, extreme high blood sugar can lead to coma or death. Increases in cholesterol and weight gain have also been reported with medicines like GEODON.
Tell your doctor if you are pregnant or intend to become pregnant. Breast feeding is not recommended.
If you experience a rash, lightheadedness upon standing, or seizures, tell your doctor. Also tell your doctor if you have thoughts of suicide.
Other risks may include decreases in white blood cells (which can be serious), trouble swallowing, high prolactin levels, and impairment in judgment or motor skills. Until you know how GEODON affects you, you should not drive or operate machinery.
Do not drink alcohol while taking GEODON. Avoid becoming overheated or dehydrated. Common side effects of GEODON include:
- Feeling unusually tired or sleepy
- Nausea or upset stomach
- Abnormal muscle movements, including tremor, shuffling, and uncontrolled involuntary movements
- Increased cough/runny nose
In short-term bipolar mania clinical studies, 4.9% of GEODON-treated patients gained significant weight (7% or more of body weight) vs 3.3% for placebo.
In a long-term bipolar maintenance clinical study, patients who tolerated GEODON plus lithium or valproate (Depakote®) for 10-16 weeks were either continued on GEODON or switched to placebo for up to 6 months. During these six months, 5.6% of patients in both groups gained significant weight. These results do not include patients who did not complete the study.
In short-term schizophrenia clinical studies, 10% of GEODON-treated patients gained significant weight vs 4% for placebo.
Since there is no experience regarding the safety of administering GEODON for Injection to schizophrenic patients already taking oral GEODON, the practice of coadministration is not recommended.
GEODON ® (ziprasidone HCl) is a prescription medicine. It is used to treat acute manic or mixed episodes associated with bipolar disorder and to treat symptoms of schizophrenia. GEODON is also used as maintenance treatment of bipolar disorder when added to lithium or valproate (Depakote). For full symptoms and diagnostic criteria, see the
DSM-IV-TR® (2000). GEODON may increase the risk of changes to your heart rhythm. In some cases these types of changes can be fatal though it is unknown whether this is the case with GEODON. It is important to talk to your doctor about this potential side effect, as your doctor may consider a different medicine first.
Patients should always ask their doctors for medical advice about adverse events.
You may report an adverse event related to Pfizer products by calling
Please see Full Prescribing Information, including BOXED WARNING and Patient Information.
Terms and Conditions
By using the GEODON Co-Pay Card, you acknowledge that you currently meet the eligibility criteria and will comply with the following terms and conditions.
- Offer is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare, or other federal or state health care programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico formerly known as “La Reforma de Salud”)
- Offer is not valid for prescriptions that are eligible to be reimbursed by private insurance plans or other health or pharmacy benefit programs that reimburse you for the entire cost of your prescription drugs
- By using the Card, patients may receive savings of up to $250 per fill and pay a minimum of $4 per fill. The Card is good for a maximum of $3,000 per year. After a maximum of $3,000, patient will pay monthly out-of-pocket costs
- The Card may be used once per month for the life of the program
- You must deduct the value of the Card from any reimbursement request submitted to your insurance plan, either directly by you or on your behalf
- Card is not valid for Massachusetts residents whose prescriptions are covered in whole or in part by third-party insurance, or where otherwise prohibited by law
- Card cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription
- Card will be accepted only at participating pharmacies
- Card is not health insurance
- Offer good only in the US and Puerto Rico
- Card is limited to 1 per person during this offering period and is not transferable
- Pfizer reserves the right to rescind, revoke, or amend this offer without notice
- No membership fee
- Offer expires 12/31/2017
- For further information call 1-800-725-9655. Pfizer Inc, 235 E. 42nd Street, New York, NY 10017